Lynx Dx

06/09/2026

When you think about men's health, what comes to mind?

For us at Lynx Dx, it’s this: Many men delay or avoid prostate cancer screening because they mistakenly believe it requires an invasive exam.

But it doesn't have to. Our mission is to make prostate cancer testing less invasive, more accessible, and more precise, so every man is empowered to take control of their health.

This Men's Health Month, visit LynxDx.com to learn more about MyProstateScore 2.0 (MPS2), a non-invasive, urine-based prostate cancer risk assessment and share the link with someone you care about.

----

If you’re a physician looking for a better option for prostate cancer risk assessment, MyProstateScore 2.0 (MPS2) fits seamlessly into practice workflows:

• Best‑in‑class accuracy
• No DRE required
• At‑home or in‑office collection
• No temperature‑controlled shipping

Request more information here: https://www.lynxdx.com/mps2-request-consultation/

06/01/2026

We’re on the road this June!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.lynxdx.com/

05/19/2026

Thank you to all who made remarkable! We left inspired by the meaningful dialogue sparked this year in Washington D.C..

AUA2026 reinforced the importance of continued advancement in men’s healthcare. Through innovations like MyProstateScore 2.0 (MPS2), we’re proud to support healthcare providers dedicated to improving patient care every single day through accessible, non-invasive prostate cancer testing.

If we didn’t have a chance to connect at AUA2026, connect with us here on Facebook: follow us or leave a comment on this post! Let's improve men's health together!

—

MyProstateScore 2.0 (MPS2)

If you’re a physician looking for a better option for prostate cancer risk assessment, MPS2 is a non-invasive, urine-based test that fits seamlessly into practice workflows.

• Best-in-Class accuracy
• No DRE required
• At-Home or In-Office collection
• No Temperature-Controlled Shipping

Request more information: https://www.lynxdx.com/mps2-request-consultation/

05/16/2026

Today at , our team shared insights contributing to the foundation of prostate cancer detection.

At Lynx Dx, we’re committed to translating scientific discovery into innovative testing options that improve patient care.

Read our team's latest research on active surveillance: https://www.lynxdx.com/2026/05/news/activesurveillance/?utm_source=Facebook&utm_medium=Social_Media&utm_campaign=AUA26&utm_term=ActiveSurveillance&utm_content=hyperlink

Visit us at Booth 1209 and follow us here on Facebook to keep the conversation going!

—

MyProstateScore 2.0 (MPS2)

If you’re a physician looking for a better option for prostate cancer risk assessment, MPS2 is a non-invasive, urine-based test that fits seamlessly into practice workflows.

• Best-in-Class accuracy
• No DRE required
• At-Home or In-Office collection
• No Temperature-Controlled Shipping

Request more information: https://www.lynxdx.com/mps2-request-consultation/

05/15/2026

The future of urology is being shaped by the community at . We’re connecting with colleagues across the field and diving into the insight-packed agenda.

Visit us at Booth 1209! And don't miss us tomorrow, May 16, as members of our Lynx Dx team share core insights on the evolving understanding of prostate cancer biology and active surveillance.

📅 IP31-02: Non-Invasive Urine Test Predicts the Need for Biopsy in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI

🕤 Saturday, May 16 from 9:30am - 11am

📍 Room 145AB

In the meantime, catch up on our team's latest active surveillance research, recently published in The Journal of Urology. https://www.lynxdx.com/2026/05/news/activesurveillance/?utm_source=Facebook&utm_medium=Social_Media&utm_campaign=AUA26&utm_term=ActiveSurveillance&utm_content=hyperlink

—

MyProstateScore 2.0 (MPS2)

If you’re a physician looking for a better option for prostate cancer risk assessment, MPS2 is a non-invasive, urine-based test that fits seamlessly into practice workflows.

• Best-in-Class accuracy
• No DRE required
• At-Home or In-Office collection
• No Temperature-Controlled Shipping

Request more information: https://www.lynxdx.com/mps2-request-consultation/

05/13/2026

We’re looking forward to connecting with the American Urological Association community at , May 15-18 in Washington, D.C.!

Join our Lynx Dx team Saturday, May 16 as we share perspectives on the ongoing advancement of prostate cancer detection and active surveillance.

📅 IP31-02: Non-Invasive Urine Test Predicts the Need for Biopsy in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI

🕤 Saturday, May 16 from 9:30am - 11am

📍 Room 145AB

If you’re attending AUA this year, visit us at booth #1209!

Haven’t registered yet? Register now: https://www.auanet.org/AUA2026/register

—

MyProstateScore 2.0 (MPS2)

If you’re a physician looking for a better option for prostate cancer risk assessment, MPS2 is a non-invasive, urine-based test that fits seamlessly into practice workflows.

• Best-in-Class accuracy
• No DRE required
• At-Home or In-Office collection
• No Temperature-Controlled Shipping

Request more information: https://www.lynxdx.com/mps2-request-consultation/

05/06/2026

Excited to see Urology Times highlight the recently published validation study for MyProstateScore 2.0 – Active Surveillance (MPS2-AS).

The study demonstrated strong performance compared to mpMRI for detecting upgrading in men on active surveillance and showed the potential to reduce unnecessary biopsies.

Read the Urology Times coverage here: https://www.urologytimes.com/view/mps2-as-outperforms-mpmri-for-prostate-cancer-upgrading-during-active-surveillance

----

MPS2-AS is investigational and not yet commercially available.

In a multisite validation study, the urine-based MPS2-AS assay outperformed mpMRI for detecting disease upgrading in men with GG1 prostate cancer on active surveillance and could reduce unnecessary biopsies.

05/05/2026

New research published in The Journal of Urology marks an important validation milestone for a non-invasive approach to monitoring men with low-risk prostate cancer on active surveillance.

In a multisite validation study, MyProstateScore 2.0 – Active Surveillance (MPS2-AS) — an investigational urine test developed by Lynx Dx — demonstrated strong performance in identifying cancers at risk of upgrading and reducing unnecessary biopsies.

MPS2-AS is the first urine-based biomarker test validated to predict risk of progression in men on active surveillance. When available, it is designed to provide more personalized, patient-friendly monitoring.

Learn more: https://www.lynxdx.com/2026/05/news/activesurveillance/?utm_source=Facebook&utm_medium=Social_Media&utm_campaign=ActiveSurveillance&utm_term=Announcement&utm_content=hyperlink

------

MPS2-AS is not yet commercially available — follow us for the latest updates and developments.

Could a simple urine test replace repeat prostate biopsies? A new study says yes — with 97% sensitivity for detecting cancer progression in men on active surveillance.

05/04/2026

We’re on the road this May!

Come meet the Lynx Dx team at and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.LynxDx.com/

04/08/2026

We’re on the road this April!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://www.lynxdx.com/